P-gp、TopoⅡ在非小细胞肺癌中的表达

EXPRESSION OF P- gp、 TopoⅡ IN NON-SMALL CELL LUNG CANCER

为明确化疗前非小细胞肺癌 (nonsm all cell lung cancer,NSCL C)中 P-糖蛋白 (P- Glycoprotein,P- gp)、拓扑异构酶 (Topoisomerase ,Topo )的不同表达与 NSCL C的组织类型、细胞分化程度、 TNM分期是否相关 ,是否存在原发耐药 ,是否影响 NSCL C患者的预后 ,本实验采用 S- P免疫组化方法 ,检测 97例化疗前 NSCL C患者中 P- gp、 Topo 的表达情况。结果表明 :P- gp在腺癌中高表达 ,在有淋巴结转移的病例中高表达 ,且 P- gp阴性或弱阳性表达的患者预后较好 ;Topo 在鳞癌中高表达 ,阳性表达的患者预后较好。提示 :NSCL C中存在着原发耐药 ,P- gp和 Topo 在表达上虽不具有相关性 ,但两者表达程度及其交互作用都是 NSCL

The aim of this study is to elucidate whether primary drug resistant protein P- Glycoprotein( P- gp) and Topoisomerase ( Topo ) exist in untreated NSCLC patients and whether their expressions are correlated to histological type degree of differentiation and whetherthey affect TNM stage and prognosis of NSCLC patients.The expressions of P- gp and Topo were examined using S- P immunohistochemical method in97samples of primary non- samll lung carcinoma before treated by chemotherapy.The result indicated that the positive rate of P- gp was high in adenocarcinoma and in the cases with lymph node metastasis.Patients whose tumors did not express P- gp survived significantly longer than patients whose tumors had more than50 % cells expressing P- gp.The positive rate of Topo was high in squamous cell carcinoma.Patients whose tumor did express Topo survived longer.Thus it may be concluded that the primary drug resistance exist in NSCLC.Although there is no significant correlation between the expression of P- gp and Topo ,their expressions and the correlation of them are factors which affect prognosis.